Table 1

Patient demographics at time of biopsy

CharacteristicN%
Total cases*138100
Sex
 Male6043.48
 Female7856.52
Age, years
 Median65
 IQR56–72
ICI therapy
 Anti-PD-1/PD-L110273.91
  Monotherapy8057.97
  Plus chemotherapy107.25
  Plus targeted therapy128.70
 Anti-CTLA-4/anti-PD-13122.46
 Anti-CTLA-453.62
  Monotherapy42.90
  Plus chemotherapy10.72
Malignancy
 Melanoma5136.96
 NSCLC2618.84
 Genitourinary1510.87
 Gynecologic128.70
 Breast75.07
 Hematologic75.07
 Other†2014.49
  • *Includes 127 unique patients.

  • †Other malignancies: squamous cell carcinoma of the head and neck (6), primary neurologic (4), sarcoma (3), small-cell lung cancer (3), endocrine (2), gastrointestinal (1), mesothelioma (1).

  • CTLA-4, cytotoxic T lymphocyte antigen-4; ICI, immune checkpoint inhibitor; NSCLC, non-small cell lung cancer; PD-1/PD-L1, programmed cell death 1/programmed cell death ligand 1.